The therapeutic potential of neuronal KCNQ channel modulators

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 6, 2003, Pages 737-748

  Gribkoff, Valentin K ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Cognition enhancement; Epilepsy; KCNQ channel inhibitors; KCNQ channel openers; Kv7.2 7.5; Migraine; Neuronal KCNQ channels; Neuropathic pain; Potassium (K+) channel

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; CHOLINESTERASE INHIBITOR; FLUPIRTINE; GABAPENTIN; LINOPIRDINE; MEMANTINE; N [1 (3 MORPHOLIN 4 YLPHENYL)ETHYL] 3 PHENYLACRYLMIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; RETIGABINE; SCOPOLAMINE; UNCLASSIFIED DRUG;

BENIGN CHILDHOOD EPILEPSY; COGNITION; COGNITIVE DEFECT; CONGENITAL DEAFNESS; DEGENERATIVE DISEASE; DRUG INDUSTRY; DRUG SYNTHESIS; DRUG TARGETING; EPILEPSY; HUMAN; IDIOPATHIC DISEASE; LONG QT SYNDROME; MEMBRANE CURRENT; MENTAL DISEASE; MIGRAINE; MOOD DISORDER; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; PATENT; REVIEW; SIDE EFFECT;

ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ANTICONVULSANTS; COGNITION DISORDERS; DRUG DESIGN; EPILEPSY; HUMANS; ION TRANSPORT; KCNQ POTASSIUM CHANNELS; KCNQ1 POTASSIUM CHANNEL; LONG QT SYNDROME; MICE; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; NEURONS; NOOTROPIC AGENTS; PAIN; POTASSIUM; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED; RECEPTORS, MUSCARINIC; RECOMBINANT FUSION PROTEINS; XENOPUS;

EID: 0346957063     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.6.737     Document Type: Review

References (100)

1. COOPER EC, JAN LY: M-channels: neurological diseases, neuromodulation, and drug development. Arch. Neurol. (2003) 60:496-500.
2. JENTSCH TJ: Neuronal KCNQ potassium channels: physiology and role in disease. Nat. Rev. Neurosci. (2000) 1:21-30.
3. ROBBINS J: KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol. Ther. (2001) 90:1-19.
4. BIEVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403-406.
5. CHARLIER C, SINGH NA, RYAN SG et al.: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Genet. (1998) 18:53-55.
6. SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25-29.
7. PICARD S, LACROIX P: QT interval prolongation and cardiac risk assessment for novel drugs. Curr. Opin. Invest. Drugs (2003) 4:303-308.
8. GRIBKOFF VK, STARRETT JE: An assessment of the present and future roles of non-ligand gated ion channel modulators as CNS therapeutics. Expert Opin. Pharmacother. (1999) 1:61-70.
9. WICKENDEN AD: Potassium channels as anti-epileptic drug targets. Neuropharmacology (2002) 43:1055-1060.
10. FORD JW, STEVENS EB, TREHERNE JM et al.: Potassium channels: gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. Prog. Drug Res. (2002) 58:133-168.
11. WILLUMSEN NJ, BECH M, OLESEN SP et al.: High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptors Channels (2003) 9:3-12.
12. GRIBKOFF VK, STARRETT JE: Advances in technologies for the discovery and characterization of ion channel modulators: focus on potassium channels. Annu. Rep. Med Chem. (2002) 37:237-246.
13. ARMSTRONG C: Voltage-gated K channels. Sci. STKE (2003) re10:1-7.
14. + channels in ontogeny and gliosis: a hypothesis based upon studies on Muller cells. Glia (2000) 29:35-44.
15. JACKSON WF: Ion channels and vascular tone. Hypertension (2000) 35:173-178.
16. MATHIE A, CLARKE CE, RANATUNGA KM, VEALE EL: What are the roles of the many different types of potassium channel expressed in cerebellar granule cells? Cerebellum (2003) 2:11-25.
17. VOGALIS F: Potassium channels in gastrointestinal smooth muscle. J. Autonom. Pharmacol. (2000) 20:207-219.
18. WONDERLIN WF, STROBL JS: Potassium channels, proliferation and G1 progression. J. Membr. Biol. (1996) 154:91-107.
19. YELLEN G: The voltage-gated potassium channels and their relatives. Nature (2002) 419:35-42.
20. ARCHER SL: Potassium channels and erectile dysfunction. Vascul. Pharmacol. (2002) 38:61-71.
21. GRIBKOFF VK, STARRETT JE, DWORETZKY SI: Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist (2001) 7:166-177.
22. + channels. Prog. Biophys. Mol. Biol. (2003) 81:133-176.
23. JOHNSON D, CHRISTIE BR, FRICK A et al.: Active dendrites, potassium channels and synaptic plasticity. Philos. Trans. R. Soc. Lond. B Biol. Sci. (2003) 358:667-674.
24. JAHANGIR A, SHEN W, TERZIC A: Potassium channel openers: therapeutic potential in cardiology and medicine. Expert Opin. Pharmacother. (2001) 2:1995-2010.
25. GRIBKOFF VK, STARRETT JE, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471-477.
26. SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P et al.: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888-898.
27. DUPUIS DS, SCHRODER RL, JESPERSEN T et al.: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. J. Pharmacol. (2002) 437:129-137.
28. GRIBKOFF VK, CHAMPIGNY G, BARBRY P et al.: The substituted benzimidazolone NS004 is in opener of the cystic fibrosis chloride channel. J. Biol. Chem. (1994) 269:10983-10986.
29. MCKAY MC, DWORETZKY SI, MEANWELL NA et al.: Opening of large-conductance calcium-activated potassium channels by the substituted benzimidazolone NS004. J. Neurophysiol. (1994) 71:1873-1882.
30. GRIBKOFF VK, STARRETT JE, DWORETZKY SI: The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv. Pharmacol (1997) 37:319-348.
31. YUAN A, SANTI CM, WEI A et al.: The sodium-activated potassium channel is encoded by a member of the Slo gene family. Neuron (2003) 37:765-773.
32. LIU Y, LIU D, HEATH L et al.: Direct activation of an inwardly rectifying potassium channel by arachidonic acid. Mol. Pharmacol. (2001) 59:1061-1068.
33. + channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes. J. Physiol. (2001) 537:811-827.
34. + channel in apical membranes of rat cortical-collecting duct (CCD). J. Gen. Physiol. (2002) 120:603-615.
35. 2 site in the N terminus. J. Biol. Chem. (2003) 278:10500-10505.
36. BIENENGRAEBER M, ALEKSEEV AE, ABRAHAM MR et al.: ATPase activity of the sulphonylurea receptor: a catalytic function for the KATP channel complex. FASEB J. (2000) 14:1943-1952.
37. YANG WP, LEVESQUE PC, LITTLE WA et al.: Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J. Biol. Chem. (1998) 273:19419-19423.
38. OKADA M, ZHU G, HIROSE S et al.: Age-dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy Res. (2003) 53:81-94.
39. BIEVERT C, STEINLEIN OK: Structural and mutational analysis of KCNQ2, the major gene locus for benign familial neonatal convulsions. Hum. Genet. (1999) 104:234-240.
40. + channel. Proc. Natl. Acad. Sci. USA (2001) 98:12272-12277.
41. SINGH N, WESTENSKOW P, CHARLIER C et al.: KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain (2003) 126:1-12.
42. KUBISCH C, SCHROEDER BC, FRIEDRICH T et al.: KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness. Cell (1999) 96:437-446.
43. + channel mutated in a form of dominant deafness, is expressed in the inner ear and central auditory canal. Proc. Natl. Acad. Sci. USA (2000) 97:4333-4338.
44. LERCHE C, SCHERER CR, SEEBOHM G et al.: Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-channel diversity. J. Biol. Chem. (2000) 275:22395-22400.
45. SCHROEDER BC, HECHENBERGER M, WEINREICH F, KUBISCH C, JENTSCH TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-channel currents. J. Biol. Chem. (2000) 275:24089-24095.
46. FRIEDEL HA, FITTON A: Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs (1993) 45:548-569.
47. HOVINGA CA. Novel anticonvulsant medications in development. Expert Opin. Invest. Drugs (2002) 11:1387-1406.
48. MAIN MJ, CRYAN JE, DUPERE JR et al.: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. (2000) 58:253-262.
49. PASSMORE GM, SELYANKO AA, MISTRY M et al.: KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. (2003) 23:7227-7236.
50. TATULIAN L, DELMAS P, ABOGADIE FC, BROWN DA: Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J. Neurosci. (2001) 21:5535-5545.
51. TATULIAN L, BROWN DA: Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J. Physiol. (2003) 549:57-63.
52. RUNDFELDT C, NETZER R: Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and voltage gated ion channels. Arzneimittelfoschung (2000) 50:1063-1070.
53. YUS-NAJERA E, MUNOZ A, SALVADOR N et al.: Localization of KCNQ5 in the normal and epileptic human temporal neocortex and hippocampal formation. Neuroscience (2003) 120:353-364.
54. TINEL N, LAURITZEN I, CHOUABE C, LAZDUNSKI M, BORSOTTO M: The KCNQ2 potassium channel: splice variants, functional and developmental expression. Brain localization and comparison with KCNQ3. FEBS Lett. (1998) 438:171-176.
55. PAN Z, SELYANKO AA, HADLEY JK, BROWN DA, DIXON JE, MCKINNON D: Alternative splicing of KCNQ2 potassium channel transcripts contributes to the functional diversity of M-currents. J. Physiol. (2001) 531:347-358.
56. NAKAMURA M, WATANABE H, KUBO Y et al.: KQT2, a new putative potassium channel family produced by alternative splicing. Isolation, genomic structure, and alternative splicing of the putative potassium channels. Receptors Channels (1998) 5:255-271.
57. SMITH JS, IANNOTTI CA, DARGIS P, CHRISTIAN EP, AIYAR J: Differential expression of KCNQ2 splice variants: implications to M current function during development. J. Neurosci. (2001) 15:1096-1103.
58. ADAMS PR, BROWN DA, CONSTANTI A: Pharmacological inhibition of the M-current. J. Physiol. (1982) 332:223-262.
59. WANG HS, PAN Z, SHI W et al.: KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (1998) 282:1890-1893.
60. HADLEY JK, PASSMORE GM, TATULIAN L et al.: Stoichiometry of expressed KCNQ2/KCNQ3 potassium channels and subunit composition of native ganglionic M channels deduced from block by tetraethylammonium. J. Neurosci. (2003) 23:5012-5019.
61. SHAH MM, MISTRY M, MARSH SJ, BROWN DA, DELMAS P: Molecular correlates of the M-current in cultured rat hippocampal neurons. J. Physiol. (2002) 544:29-37.
62. SUH BC, HILLE B: Recovery from muscarinic modulation of M current channels requires phosphatidylinositol 4,5-bisphosphate synthesis. Neuron (2002) 35:507-520.
63. (2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents. Neuron (2003) 37:963-975.
64. HOSHI N, ZHANG JS, OMAKI M et al.: AKAP150 signalling complex promotes suppression of the M-current by muscarinic agonists. Nature Neurosci. (2003) 6:564-571.
65. YUS-NAJERA E, SANTANA-CASTRO I, VILLARROEL A: The identification and characterization of a noncontinuous calmodulin-binding site in noninactivating voltage-dependent KCNQ potassium channels. J. Biol. Chem. (2002) 277:28545-28553.
66. WEN H, LEVITAN IB: Calmodulin is an auxiliary subunit of KCNQ23 potassium channels. J. Neurosci. (2002) 22:7991-8001.
67. GAMPER N, STOCKLAND JD, SHAPIRO MS: Subunit-specific modulation of KCNQ potassium channels by Src tyrosine kinase. J. Neurosci. (2003) 23:84-95.
68. FINNERUP NB, GOTTRUP H, JENSEN TS: Anticonvulsants in central pain. Expert Opin. Pharmacother. (2002) 3:1411-1420.
69. CORTELLI P, PIERANGELI G: Chronic pain - autonomic interactions. Neurol. Sci. (2003) 24:S68-S70.
70. LIDBECK J: Central hyperexcitability in chronic musculoskeletal pain: a conceptual breakthrough with multiple clinical implications. Pain Res. Manag. (2002) 7-81-92.
71. PONGS O: Voltage-gated potassium channels: from hyperexcitability to excitement. FEBS Lett. (1999) 452:31-35.
72. ++ model in the hippocampal slice preparation. Epilepsy Res. (2000) 38:53-66.
73. ROSTOCK A, TOBER C, RUNDFELDT C et al.: D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. (1996) 23:211-223.
74. TOBER C, ROSTOCK A, RUNDFELDT C, BARTSCH R: D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol. (1996) 303:163-169.
75. WU YJ, BOISSARD CG, GRECO C et al.: (S)-N-[1-(3-morpholin-4-ylphenyl]-3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine. J. Med. Chem. (2003) 46:197-200.
76. WHEELER G: Gabapentin. Pfizer. Curr. Opin. Invest. Drugs (2002) 3:470-477.
77. BLACKBURN-MUNRO G, JENSEN BS: The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur. J. Pharmacol. (2003) 460:109-116.
78. SHIMAZAWA M, HARA H: An experimental model of migraine with aura: cortical hypoperfusion following spreading depression in the awake and freely moving rat. Clin. Exp. Pharmacol. Physiol. (1996) 23:890-892.
79. WELCH KM: Concepts of migraine headache pathogenesis: insights into mechanisms of chronicity and new drug targets. Neurol. Sci. (2003) 24:S149-S153.
80. BARTSCH T, GOADSBY PJ: The trigeminocervical complex and migraine: current concepts and synthesis. Curr. Pain Headache Rep. (2003) 7:371-376.
81. OLIVER D, KNIPPER M, DERST C, FAKLER B: Resting potential and submembrane calcium concentration of inner hair cells in the isolated mouse cochlea are set by KCNQ-typc potassium channels. J. Neurosci. (2003) 23:2141-2149.
82. NOUVIAN R, RUEL J, WANG J, GUITTON MJ, PUJOL R, PUEL JL: Degeneration of sensory outer hair cells following pharmacological blockade of cochlear KCNQ channels in the adult guinea pig. Eur. J. Neurosci. (2003) 17:2553-2562.
83. SANGUINETTI MC: Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann. NY Acad. Sci. (1999) 868:406-413.
84. DEDEK K, WALDEGGER S: Colocalization of KCNQ1/KCNE channel subunits in the mouse gastrointestinal tract. Pflugers Arch. Eur. J. Pharmacol. (2001) 442:896-902.
85. ZACZEK R, CHORVAT RJ, BROWN BS: Linopirdine: pharmacology of a neurotransmitter release enhancer. CNS Drug Rev. (1997) 3:103-119.
86. ZACZEK R, CHORVAT RJ, SAYE JA et al.: Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyrinylmethyl)-9(10H)-anthtacenone and 10,10-bis (2-fluoro-4-pyrinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. J. Pharmacol. Exp. Ther. (1998) 285:724-730.
87. SAFER DJ: The central effects of scopolamine in man. Biol. Psychiatry (1971) 3:347-355.
88. GAGE FH, CHEN KS, BUZSAKI G, ARMSTRONG D: Experimental approaches to age-related cognitive impairments. Neurobiol. Aging (1988) 9:645-655.
89. EBERT U, KIRCH W: Scopolamine model of dementia: electroencephalogram findings and cognitive performance. Eur. J. Clin. Invest. (1998) 28:944-949.
90. SUNDERLAND T, TARIOT PN, WEINGARTNER H et al.: Pharmacologic modeling of Alzheimer's disease. Prog. Neuropsychopharmacol. (1986) 10:599-610.
91. BARTUS RT, DEAN RL, BEER B, LIPPA AS: The cholinergic hypothesis of geriatric memory dysfunction. Science (1982) 217:408-414.
92. FIBIGER HC: Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. (1991) 14:220-223.
93. BLOKLAND A: Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Brain Res. Rev. (1995) 21:285-300.
94. SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y: Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors. Curr. Med. Chem. (2000) 7:303-339.
95. ROGAWSI MA, WENK GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. (2003) 9:275-308.
96. BLAND BH: The physiology and pharmacology of hippocampal formation θ rhythms. Prog. Neurobiol. (1986) 26:1-54.
97. BARNES JC, ROBERTS FF: Central effects of muscarinic agonists and antagonists on hippocampal θ rhythm and blood pressure in the anaesthetized rat. Eur. J. Pharmacol. (1991) 195:233-240.
98. KINNEY GG, PATINO P, MERMET-BOUVIER Y, STARRETT JE, GRIBKOFF VK: Cognition-enhancing drugs increase stimulated hippocampal θ rhythm amplitude in the urethane-anesthetized rat. J. Pharmacol. Exp. Ther. (1999) 291:99-106.
99. DIAMOND DM, DUNWIDDIE TV, ROSE GM: Characteristics of hippocampal primed burst potentiation in vitro and in the awake rat. J. Neurosci. (1988) 8:4079-4088.
100. TOMBAUGH GC, ROWE WB, CHOW AR, MICHAEL TH, ROSE GM: θ-Frequency synaptic potentiation in CA1 in vitro distinguishes cognitively impaired from unimpaired aged Fischer 344 rats. J. Neurosci. (2002) 15:9932-9940.